PD-Rx Pharmaceuticals (OTCPK:PDRX) - Share price, News & Analysis

PDRX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

PDRX Stock Overview

PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States.

Rewards

Price-To-Earnings ratio (2.8x) is below the US market (14.3x)

Became profitable this year

Risk Analysis

Shares are highly illiquid

High level of non-cash earnings

Does not have a meaningful market cap ($5M)

PD-Rx Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PD-Rx Pharmaceuticals
Historical stock prices
Current Share Price	US$3.15
52 Week High	US$3.15
52 Week Low	US$2.00
Beta	0.35
1 Month Change	5.00%
3 Month Change	n/a
1 Year Change	12.70%
3 Year Change	-30.00%
5 Year Change	-46.15%
Change since IPO	110.00%

Shareholder Returns

	PDRX	US Healthcare	US Market
7D	0%	6.9%	4.0%
1Y	12.7%	2.8%	-20.5%

Return vs Industry: PDRX exceeded the US Healthcare industry which returned 1.2% over the past year.

Return vs Market: PDRX exceeded the US Market which returned -20.8% over the past year.

Price Volatility

Is PDRX's price volatile compared to industry and market?
PDRX volatility
PDRX Average Weekly Movement	n/a
Healthcare Industry Average Movement	9.3%
Market Average Movement	7.9%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.1%

Stable Share Price: Insufficient data to determine PDRX's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine PDRX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1986	n/a	Robert Holsey	https://www.pdrx.com

PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company provides approximately 2,600 prepackaged medications; and creams, ointments, ophthalmics, otics, liquids, suspensions, etc. It also offers PD-Rx Net, a web-based application that tracks prescriptions filled at the point of care and print prescription labels for prescription that filled onsite; and manual dispensing system that provides 10 recordkeeping labels to match the 10 bottle trays as a convenient handling package for physician dispensing customers. In addition, the company provides professional assistance by staffed pharmacists and physicians; and pharmaceutical sampling program design to reduce MCO’s pharmaceutical costs, as well as allows medical professionals to offer pre-filled prescriptions to patients free of charge.

PD-Rx Pharmaceuticals Fundamentals Summary

How do PD-Rx Pharmaceuticals's earnings and revenue compare to its market cap?
PDRX fundamental statistics
Market Cap	US$5.18m
Earnings (TTM)	US$1.86m
Revenue (TTM)	US$21.60m

2.8x

P/E Ratio

0.2x

P/S Ratio

Is PDRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
PDRX income statement (TTM)
Revenue	US$21.60m
Cost of Revenue	US$14.65m
Gross Profit	US$6.96m
Other Expenses	US$5.10m
Earnings	US$1.86m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	1.13
Gross Margin	32.20%
Net Profit Margin	8.59%
Debt/Equity Ratio	0.0%

How did PDRX perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is PDRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PDRX?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for PDRX. This is calculated by dividing PDRX's market cap by their current preferred multiple.
What is PDRX's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$5.18m

PDRX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.1x
Enterprise Value/EBITDA	2.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does PDRX's PE Ratio compare to its peers?

PDRX PE Ratio vs Peers

The above table shows the PE ratio for PDRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PE	Estimated Growth	Market Cap
Peer Average	15.5x

Forward PE

Price-To-Earnings vs Peers: PDRX is good value based on its Price-To-Earnings Ratio (2.8x) compared to the peer average (15.5x).

Price to Earnings Ratio vs Industry

How does PDRX's PE Ratio compare vs other companies in the U.S. Healthcare Industry?

Price-To-Earnings vs Industry: PDRX is good value based on its Price-To-Earnings Ratio (2.8x) compared to the US Healthcare industry average (18.4x)

Price to Earnings Ratio vs Fair Ratio

What is PDRX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PDRX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	2.8x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PDRX's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of PDRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PDRX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PDRX's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PDRX's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is PD-Rx Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

12.3%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PD-Rx Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Examine PD-Rx Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access PD-Rx Pharmaceuticals's filings and announcements here.

Past Performance

How has PD-Rx Pharmaceuticals performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

13.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PDRX has a high level of non-cash earnings.

Growing Profit Margin: PDRX became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: PDRX's earnings have grown by 13.2% per year over the past 5 years.

Accelerating Growth: PDRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: PDRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (9.5%).

Return on Equity

High ROE: PDRX's Return on Equity (21.9%) is considered high.

Discover strong past performing companies

Financial Health

How is PD-Rx Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: PDRX's short term assets ($10.0M) exceed its short term liabilities ($2.4M).

Long Term Liabilities: PDRX has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: PDRX is debt free.

Reducing Debt: PDRX had no debt 5 years ago.

Debt Coverage: PDRX has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: PDRX has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

Dividend

What is PD-Rx Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PDRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PDRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PDRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PDRX's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PDRX has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

US$59k

CEO Compensation

CEO

Robert Holsey (68 yo)

no data

Tenure

US$58,519

Compensation

Dr. Robert D. Holsey D.O., R.Ph. has been a Director of Pd-rx Pharmaceuticals Inc. since 1986 and serves as President, Chief Executive Officer and Chairman of the Board and a practicing physician. Dr. Hols...

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/06/23 00:00
End of Day Share Price	2022/05/26 00:00
Earnings	2021/06/30
Annual Earnings	2021/06/30